Pursuing medicine in beauty
Enhancing the growing relationship between beauty and medicine, Chlitina’s parent company, Lifeng, has entered into a strategic cooperation agreement with Tongji University to create the Tongji University-Lifeng Institute of Regenerative Medicine.
In celebration of its 20th anniversary in China, Chlitina invited its beauticians and associates to the Mercedes-Benz Arena in Shanghai on 25th June 2017.
Since its initial launch two decades ago, which saw its founder Dr Chen Wu-kang use amino acids, and develop and bring to market a skin care product designed to repair damaged skin, Chlitina has continued to innovate its product formulations, branding, organisation and management, distribution channels and capital, to appeal to China’s changing cosmetics landscape.
Skin care evolution
It has invested in training at its Germes Training Institute and has launched its Beauty Health Happiness e-commerce platform to grow the franchise, overcome inventory issues and pursue the digitisation trend.
Amid the progress of society, Chlitina is now looking towards the next stage of skin care evolution stating in a recent press release how “traditional skin care cannot satisfy customers’ needs anymore, albeit in the high-end medical beauty sector dedicated to anti-ageing treatments”.
As “innovative technologies for regenerative medicine are emerging”, Chlitina focuses on raising its brand profile in the medical beauty industry by providing value through exploring regenerative medicine.
“Tongji University is a venerable and prestigious higher education institution that has been included in Project 211 and Project 985 national programs for key universities and colleges,” said Joanna Chen, CEO of CHL.
Stem cell research
“Chlitina intends to cooperate with experts from Tongji University in order to deepen research on stem cells differentiation, establish a stem cell bank, carry out skin tests and commercialise research results so they can be applied to skin care and beauty services and products”, Chen went on to say.
As part of its longer-term strategic plan, Chlitina hopes that in the next 3 to 5 years, the company will be able to “apply stem cell research to the treatment of inflammatory skin diseases and skin ageing, bringing new benefits to medical beauty and anti-ageing treatments”.
Reiterating the insights of William Haseltine, former Harvard Medical School, Harvard School of Public Health Professor and cancer and genomics expert, Chlitina emphasises that with regenerative medicine: “we don’t necessarily need to invent new things just now; the key is to make high-tech drugs more available and to expand high-quality research programmes, so that the results of scientific research can be offered in a correct and appropriate way to the masses”.
“The goal of their strategic agreement is to build together a research and development centre for technologies and products derived from stem cell therapy that will serve as a cooperation base for innovative products and research,” highlighted Zhang Jun, Professor, Tongji University School of Medicine.
Chlitina emphasises that recent estimates reveal that the global stem cell research market will weigh close to $500 bn (€436.5 bn), of which $100 bn (€87.3 bn) will come from China alone by 2020.